Ingenol Mebutate

Actinic Keratosis

Treatment

11 Active Studies for Ingenol Mebutate

Treatment for

Actinic Keratosis

What is Ingenol Mebutate

Ingenol mebutateThe Generic name of this drug

Treatment SummaryPicato (Ingenol mebutate) is a gel used to treat actinic keratosis, a skin condition caused by too much sun exposure. It was approved by the FDA in 2012. The active ingredient in Picato, PEP005, is a natural extract from the plant Euphorbia peplus that has been used traditionally to treat skin conditions like warts and cancer. PEP005 also shows promise in treating certain types of leukemia by inducing cell death in myeloid leukemia cells and acute myeloid leukemia cells.

Picatois the brand name

image of different drug pills on a surface

Ingenol Mebutate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Picato

Ingenol mebutate

2012

Effectiveness

How Ingenol Mebutate Affects PatientsIt is not yet understood how ingenol mebutate works to cause cell death in actinic keratosis.

How Ingenol Mebutate works in the bodyThe way ingenol mebutate works to treat actinic keratosis is unclear, but it is thought to work by killing cells that cause the condition. It may also reduce the activity of proteins in cells responsible for the condition. This could lead to changes in pathways that reduce the activity of cells that cause actinic keratosis.

When to interrupt dosage

The suggested dosage of Ingenol Mebutate is contingent upon the diagnosed malady. The amount of dosage fluctuates as per the strategy of delivery (e.g. Topical or Gel) specified in the table beneath.

Condition

Dosage

Administration

Actinic Keratosis

0.05 %, , 0.015 %, 0.00015 mg/mg, 0.0005 mg/mg

Topical, Gel, Gel - Cutaneous, , Gel - Topical, Cutaneous

Warnings

Common Ingenol Mebutate Drug Interactions

Drug Name

Risk Level

Description

Ingenol Mebutate Toxicity & Overdose RiskCommon side effects of using this drug include skin reactions near the site of application, headaches, swelling around the eyes, and a sore throat.

image of a doctor in a lab doing drug, clinical research

Ingenol Mebutate Novel Uses: Which Conditions Have a Clinical Trial Featuring Ingenol Mebutate?

Currently, 7 clinical trials are assessing the efficacy of Ingenol Mebutate in treating Actinic Keratosis.

Condition

Clinical Trials

Trial Phases

Actinic Keratosis

12 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Ingenol Mebutate Reviews: What are patients saying about Ingenol Mebutate?

5Patient Review

2/24/2014

Ingenol Mebutate for Red Patches from Sun Exposure on the Face or Scalp

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ingenol mebutate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is ingenol mebutate used for?

"Picato gel is used to treat a skin condition called actinic keratosis. It contains the active ingredient ingenol mebutate, which comes from a plant. This ingredient works by killing the cells that make up the scaly skin patch."

Answered by AI

Why was Picato taken off the market?

"The MHRA has announced the suspension of the marketing license for ingenol mebutate gel (Picato) due to studies demonstrating an increased risk of skin malignancies from the drug."

Answered by AI

What is ingenol mebutate topical gel?

"Nov 15, 2015Ingenol mebutate gel is used to treat actinic keratosis. Ingenol mebutate is in a class of medications called cytotoxic agents. It works by killing fast-growing cells."

Answered by AI

Is Picato gel still available?

"- LEO Pharma announced it will permanently discontinue the manufacture of Picato (ingenol mebutate) gel. The discontinuation is due to business reasons and is not related to any safety, efficacy or quality concerns. The phase-out is expected to be completed by the end of 2020."

Answered by AI

Clinical Trials for Ingenol Mebutate

Image of Cleveland Clinic, Case Comprehensive Cancer Center in Cleveland, United States.

Standard PDT + Topical Aminolevulinate + Red Light Illuminationfor Actinic Keratosis

18+

All Sexes

Cleveland, OH

This trial tests a new camera device to see if it can predict how well a treatment for skin lesions is working. #medicalresearch

Phase 2

Waitlist Available

Has No Placebo

Cleveland Clinic, Case Comprehensive Cancer CenterEdward Maytin, MD, PhD

Image of University of Arizona Cancer Center - Prevention Research Clinic in Tucson, United States.

Have you considered Ingenol Mebutate clinical trials? We made a collection of clinical trials featuring Ingenol Mebutate, we think they might fit your search criteria.

Image of Northwestern University Department of Dermatology in Chicago, United States.

Chemical Peelsfor Actinic Keratosis

18+

All Sexes

Chicago, IL

This trial is comparing photodynamic therapy to a combination of Jessner's solution and 35% TCA chemical peels to see which is more effective for treating actinic keratoses.

Phase 2

Waitlist Available

Has No Placebo

Northwestern University Department of DermatologyMurad Alam, MD

Image of Massachusetts General Hospital in Boston, United States.

Topical 5FUfor Squamous Cell Carcinoma

18+

All Sexes

Boston, MA

This trial is investigating whether a combination of two drugs can help prevent skin cancer in people who have received organ transplants.

Phase 2

Waitlist Available

FDA Approved Drug

Massachusetts General Hospital (+1 Sites)Shadmehr Demehri, MD/PHD

Image of Dayton VA Medical Center in Dayton, United States.

Fractionated Laser Resurfacingfor Actinic Keratosis

18+

All Sexes

Dayton, OH

This trial is testing if a fractionated laser resurfacing treatment can help to remove actinic keratosis, and also if it can help to reduce the levels of future actinic keratosis and other non-melanoma skin cancers, in comparison to an untreated arm. The study length is 5 years, with the first part completed in 1 day, and follow up visits at 90 days and every 6 months.

Recruiting

Has No Placebo

Dayton VA Medical CenterJeffrey B Travers, MD, PhD

PDT + Celecoxibfor Actinic Keratosis

18+

All Sexes

Fairborn, OH

This trial is designed to study whether the immunosuppression caused by PDT can be mitigated by treatment with celecoxib, compared to placebo. Subjects will be monitored for 6 and 12 months after the study.

Phase 1

Recruiting

FDA Approved Drug

Wright State PhysiciansJeffrey B Travers, MD, PhD

Have you considered Ingenol Mebutate clinical trials? We made a collection of clinical trials featuring Ingenol Mebutate, we think they might fit your search criteria.